Lumateperone: a new treatment approach for neuropsychiatric disorders.
B. Kumar, Anurag Kuhad, Astha Kuhad
págs. 713-720
Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
B Warden, P. B. Duell
págs. 721-736
β-Lactamase inhibitor peptides as the new strategies to overcome bacterial resistance
N.O. Silva, O. L. Franco, Willian Fernando Porto da Rocha
págs. 737-746
The Financial Times Global Pharmaceutical and Biotechnology Conference. Embracing Disruption for a New Era in Health (November 5-6, 2018 – London, UK).
Alexandra Kibble
págs. 747-752
New product intros (amikacin liposome inhalation suspension [new formulation], anagliptin/metformin hydrochloride [new combination], fruquintinib, gilteritinib, inotersen, larotrectinib sulfate [first-in-class], lorlatinib, moxetumomab pasudotox-tdfk, omidenepag isopropyl, vibegron).
págs. 753-756
Drugs Today 2018, 54(12)
págs. 757-789
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: